- Home
- UMAC vs ZVRA Comparison
UMAC vs ZVRA Comparison
Compare UMAC & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$9.40
Company Overview
Basic Information| Metric | UMAC | ZVRA |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 520.2M | 472.9M |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | UMAC | ZVRA |
|---|---|---|
| Price | $13.41 | $9.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $20.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 4.7M | 1.1M |
| Earning Date | 03-09-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 80.73 | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | $11,199,217.00 | ★ $106,470,000.00 |
| Revenue This Year | $134.64 | $37.27 |
| Revenue Next Year | $85.71 | $53.42 |
| P/E Ratio | ★ N/A | $6.76 |
| Revenue Growth | 101.23 | ★ 350.91 |
| 52 Week Low | $4.45 | $6.19 |
| 52 Week High | $23.38 | $13.16 |
Technical Indicators
Market Signals| Indicator | UMAC | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.40 | 51.42 |
| Support Level | $8.18 | $8.33 |
| Resistance Level | $16.52 | $9.44 |
| Average True Range (ATR) | 2.06 | 0.48 |
| MACD | -0.68 | -0.08 |
| Stochastic Oscillator | 0.75 | 24.15 |
Price Performance
Historical Comparison UMAC
ZVRA
About UMAC Unusual Machines Inc.
Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.